UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K **CURRENT REPORT** PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 Aterian, Inc. (Exact Name of Registrant as Specified in its Charter) **Delaware** 001-38937 83-1739858 (State or Other Jurisdiction (Commission (IRS Employer File Number) Identification No.) of Incorporation) Aterian, Inc. 37 East 18th Street, 7th Floor New York, NY 10003 (Address of Principal Executive Offices)(Zip Code) (347) 676-1681 (Registrant's telephone number, including area code) N/A (Former Name, or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> Common Stock, \$0.0001 par value Trading Symbol
ATER

Name of each exchange on which registered
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square

Item 2.02. Results of Operations and Financial Condition.

On August 9, 2021, Aterian, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number	Description
<u>99.1</u>	Press Release issued by Aterian, Inc., dated August 9, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATERIAN, INC.

Date: August 9, 2021 By: /s/ Yaniv Sarig

Name: Yaniv Sarig

Title: President and Chief Executive Officer



Aterian Reports Second Quarter 2021 Results

Quarterly Net Revenue Grew 14% Year-Over-Year to \$68 Million

Company is focused on steps to reduce the impact from the global shipping crisis

NEW YORK, August 9, 2021 – Aterian, Inc. (Nasdaq: ATER) ("Aterian" or the "Company") today announced results for the second quarter ended June 30, 2021. Aterian was formerly named Mohawk Group Holdings, Inc. and was renamed Aterian, Inc. on April 30, 2021.

Second Quarter 2021 Highlights

- Net revenue grew 14% year over year to \$68.2 million, compared to \$59.8 million in the second quarter of 2020.
- Gross margin improved to 48.0% compared to 46.2% in the second quarter of 2020.
- Operating income improved to \$4.5 million, which includes \$23.3 million of benefit from the change in fair-value of earn out liabilities, compared to an operating loss of \$(1.8) million in the second quarter of 2020.
- Contribution margin declined to 8.3% in Q2 2021 from 16.8% in the second quarter of 2020.
- Operating expenses for the second quarter of 2021 were \$28.3 million which is a decrease from \$29.4 million in the second quarter of 2020. Operating expenses for Q2 2021 include \$23.3 million of benefit from the change in fair-value of earn out liabilities.
- Excluding non-cash stock-based compensation and amortization of intangibles of \$6.5 million in the second quarter of 2021 and \$5.2 million in the second quarter of 2020 and \$23.3 million benefit from the change in fair-value of potential future performance based earnouts from acquisitions in 2021, fixed operating expenses for the second quarter increased as a percentage of net revenue to 45% compared to 29% in the second quarter of 2020.
- Net loss of \$(36.3) million, which includes a \$23.3 million benefit from the change in fair value of earnout liabilities, a \$(29.8) million loss from extinguishment of debt, a \$(4.4) million loss from the change in fair value of warrants, and a \$(1.9) million charge associated with a derivative liability from our term loan, increased from a net loss of \$2.9 million in the second quarter of 2020.
- Adjusted EBITDA decreased to a loss of \$(3.7) million compared to a gain of \$3.4 million in the second quarter of 2020.
- 19 new products launched in the second quarter compared to 8 in the second quarter of 2020.
- Total cash balance at June 30, 2021 increased by \$26.9 million from March 31, 2021 to \$61.9 million.

Yaniv Sarig, Co-Founder and Chief Executive Officer, commented, "This has been a challenging quarter for e-commerce marked by a global supply chain crisis, inflation and an extreme shift in consumer behavior due to the opening of brick and mortar stores after the relaxation of COVID-19 related restrictions. Despite the difficult environment and significant increase in product variable cost, our sales grew on average 20% on a proforma basis across all fourteen brands compared to the second quarter of 2019. In early July, the supply chain constraints turned into a global crisis as container rates spiked 500% compared to last year effectively going from manageable to presenting a significant risk. We believe that through relationships we have with

several large logistics companies we have a path forward to secure a sufficient number of containers for the next twelve months, at sustainable reduced costs from the current spot rates. We are gradually leveraging these new shipping relationships but additional operational changes over the next few months will be required to fully benefit from them."

Mr. Sarig added, "On the M&A front, we remain excited about the immense opportunity once current supply chain conditions become predictable again. While we had several deals in later stages of our process, we chose to not move forward primarily due to concerns relating to current freight cost impacts on the targets' future performance. We are withdrawing guidance until the operational adjustments to our supply chain are fully executed. We look forward to providing an updated outlook once we can more predictably model the cost, pricing and margins of our products going forward."

Mr. Sarig concluded, "We remain confident that we have the best in class platform to execute at scale on the highly sought after strategy of building the e-commerce consumer company of the future, despite the temporary global shipping crisis. We are committed to executing swiftly on adapting our business to the current situation and to emerging more resilient and better positioned to benefit from the massive long term expected TAM of global e-commerce."

Lender Agrees to Adjusted EBITDA Covenant Waiver

As a result of the unprecedented global supply chain crisis and its impact on the Company's financial condition, Aterian had to seek a waiver of its adjusted EBITDA loan covenant for the second quarter of 2021 from its lender, High Trail. As a result of our failure to have at least \$12 million of adjusted EBITDA for the 12 month period ended June 30, 2021, High Trail accelerated a total of \$18.7 million of the principal amount of its senior secured notes in an initial aggregate principal amount of \$110.0 million, requiring us to immediately pay an aggregate of \$21.8 million (115% of the accelerated principal amount, plus \$0.3 million of accrued but unpaid interest thereon). High Trail has agreed to waive the breach of the adjusted EBITDA covenant for June 30, 2021, effective upon receipt of a cash payment of \$10.1 million and shares of our common stock for the remaining \$11.7 million owed. The number of shares issuable to High Trail will be calculated based on the lower of 80% of (1) the daily volume weighted average price of our common stock on August 9, 2021, and (2) the average of the lowest two daily weighted average prices of our common stock during the ten day trading period ending on August 9, 2021. We are paying High Trail an aggregate of \$10.1 million in cash on August 9, 2021 and will issue the \$11.7 million of shares of common stock (with the number of shares calculated as described above) by August 11, 2021. In connection with the waiver, we also agreed to reprice High Trails' approximately 3.5 million warrants expiring in 2026 with exercise prices ranging from \$25.10 to \$33.56, such that the exercise price of such warrants will be equal to the lesser of (X) the closing price of our common stock on August 9, 2021 or (Y) the volume weighted average price of our common stock on August 9, 2021. High Trail agreed not to exercise the warrants prior to the day that is 60 days after a registration statement registering for resale the 2,666,667 shares of common stock we issued on June 15, 2021 is declared effective; however, if, at any time on or after January 7, 2022, High Trail is unable to exercise such warrants as a result of the foregoing, we agreed to pay High Trail a cash payment that will be equal to: (a) the weighted average price of our common stock on the date High Trail seeks to exercise any such warrants, minus the then-current exercise price of such warrants, multiplied by (b) the number of shares subject to the warrants that it then desires to exercise. In connection with the waiver, we also agreed to a liquidity covenant whereby we will be required to have cash of no less than \$30.0 million through October 31, 2021 as well as another liquidity covenant whereby our inventory and accounts receivable must, through October 31, 2021, be equal to \$65.0 million, less any amount of cash and cash equivalents in excess of \$30.0 million.

2021 Outlook Withdrawn

The global supply chain crisis has impacted the Company's ability to forecast shipping costs and its ability to procure inventory, and the COVID-19 pandemic continues to make near term consumer behavior patterns difficult to predict; therefore, the Company has decided to withdraw its 2021 net revenue and adjusted EBITDA guidance until such time that it has improved visibility and forecasting confidence.

Non-GAAP Financial Measures

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the "Non-GAAP Financial Measures and Reconciliations" section below.

Webcast and Conference Call Information

Aterian will host a live conference call to discuss financial results today, August 9, 2021, at 8:00 a.m. Eastern Time. To access the call, participants from within the U.S. should dial (877) 295-1077 and participants from outside the U.S. should dial (470) 495-9485 and provide the conference ID: 5258417. Participants may also access the call through a live webcast at https://ir.aterian.io/investor-relations. Please visit the website at least 15 minutes prior to the start of the call to register and download any necessary software. The archived online replay will be available for a limited time after the call in the Investor Relations section of the Aterian website.

About Aterian, Inc.

Aterian, Inc. (Nasdaq: ATER), is a leading technology-enabled consumer products platform that builds, acquires, and partners with best-inclass e-commerce brands by harnessing proprietary software and an agile supply chain to create top selling consumer products. The Company's cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine (AIMEETM), leverages machine learning, natural language processing and data analytics to streamline the management of products at scale across the world's largest online marketplaces, including Amazon, Shopify and Walmart. Aterian has thousands of SKUs across 14 owned and operated brands and sells products in multiple categories, including home and kitchen appliances, health and wellness, beauty and consumer electronics.

Forward Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements regarding inflation, consumer behavior shifts and the global supply chain crisis; our strategic decisions and defensive moves and the potential for such decisions and moves to address the global supply chain crisis; the re-engineering of our international supply chain; the belief that we have a path forward to reduce costs of container to \$6,500 on average and expectations around the volume of shipping containers needed over the next twelve months; estimates of the time needed to execute on our supply chain transformation; our ability to actively navigate and adapt; our expectations around paying our lender and issuing shares in connection with its waiver of our EBITDA covenant; and statements regarding our EBITDA and liquidity covenants with our lender. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to; those related to the global shipping crisis, our ability to continue as a going concern, our ability to meet financial covenants with our lenders, our ability to create operating leverage and efficiency when integrating companies that we acquire, including through the use of our team's expertise, the economies of scale of our supply chain and automation driven by our platform; those related to our ability to grow internationally and through the launch of products under our brands and the acquisition of additional brands; those related to the impact of COVID-19, including its impact on consumer demand, our cash flows, financial condition and revenue growth rate; our supply chain including sourcing, manufacturing, warehousing and fulfillment; our ability to manage expenses, working capital (including for PPE products) and capital expenditures efficiently; our business model and our technology

Exhibit 99.1

platform; our ability to disrupt the consumer products industry; our ability to grow market share in existing and new product categories, including PPE; our ability to generate profitability and stockholder value; international tariffs and trade measures; inventory management, product liability claims, recalls or other safety and regulatory concerns; reliance on third party online marketplaces; seasonal and quarterly variations in our revenue; acquisitions of other companies and technologies, our ability to continue to access debt and equity capital (including on terms advantageous to the Company) and the extent of our leverage and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), all of which you may obtain for free on the SEC's website at www.sec.gov.

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor Contact:

Ilya Grozovsky
Director of Investor Relations & Corp. Development
Aterian, Inc.
ilya@aterian.io
917-905-1699

ATERIAN, INC. Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)

	Decen	nber 31, 2020	June 30, 2021
ASSETS			
CURRENT ASSETS:			
Cash	\$	26,718	\$ 61,934
Accounts receivable—net		5,747	16,263
Inventory		31,582	75,514
Prepaid and other current assets		11,111	12,716
Total current assets		75,158	166,427
PROPERTY AND EQUIPMENT—net		169	1,350
GOODWILL—net		47,318	118,619
OTHER INTANGIBLES—net		31,460	69,115
OTHER NON-CURRENT ASSETS		3,349	3,552
TOTAL ASSETS	\$	157,454	\$ 359,063
LIABILITIES AND STOCKHOLDERS' EQUITY	•		
CURRENT LIABILITIES:			
Credit facility	\$	12,190	\$ _
Accounts payable		14,856	39,455
Term loan		21,600	72,791
Seller notes		16,231	9,955
Contingent earn-out liability		1,515	14,812
Accrued and other current liabilities		8,340	24,673
Total current liabilities		74,732	161,686
OTHER LIABILITIES		1,841	614
CONTINGENT EARN-OUT LIABILITY		21,016	20,986
TERM LOANS		36,483	_
Total liabilities		134,072	183,286
COMMITMENTS AND CONTINGENCIES (Note 9)			
STOCKHOLDERS' EQUITY:			
Common stock, par value \$0.0001 per share—500,000,000 shares authorized and			
27,074,791 shares outstanding at December 31, 2020; 500,000,000 shares			
authorized and 35,734,767 shares outstanding at June 30, 2021		3	3
Additional paid-in capital		216,305	487,605
Accumulated deficit		(192,935)	(311,794)
Accumulated other comprehensive income		9	(37)
Total stockholders' equity		23,382	175,777
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	157,454	\$ 359,063

ATERIAN, INC.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)

	Three Months	Ende	ed June 30,	 Six Months E	ed June 30,		
	2020		2021	2020		2021	
NET REVENUE	\$ 59,800	\$	68,188	\$ 85,428	\$	116,324	
COST OF GOODS SOLD	32,200		35,445	47,530		57,518	
GROSS PROFIT	27,600		32,743	 37,898		58,806	
OPERATING EXPENSES:			_				
Sales and distribution	18,618		39,310	32,528		64,379	
Research and development	2,451		2,324	4,732		4,452	
General and administrative	8,352		9,990	16,355		20,965	
Change in fair value of contingent earn-out liabilities	_		(23,349)	<u> </u>		(7,704)	
TOTAL OPERATING EXPENSES:	29,421		28,275	53,615		82,092	
OPERATING INCOME (LOSS)	 (1,821)		4,468	(15,717)		(23,286)	
INTEREST EXPENSE—net	1,077		4,675	2,186		9,092	
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITY	_		1,894	_		1,894	
LOSS ON EXTINGUISHMENT OF DEBT	_		29,772	_		29,772	
CHANGE IN FAIR VALUE OF WARRANT LIABILITY	_		4,387	_		34,589	
LOSS ON INITIAL ISSUANCE OF WARRANT	_		_	_		20,147	
OTHER EXPENSE (INCOME)	(6)		5	19		38	
LOSS BEFORE INCOME TAXES	 (2,892)		(36,265)	 (17,922)		(118,818)	
PROVISION FOR INCOME TAXES	45		41	45		41	
NET LOSS	\$ (2,937)	\$	(36,306)	\$ (17,967)	\$	(118,859)	
Net loss per share, basic and diluted	\$ (0.19)	\$	(1.23)	\$ (1.17)	\$	(4.26)	
Weighted-average number of shares outstanding, basic and diluted	15,425,312		29,547,781	15,308,966		27,886,582	

ATERIAN, INC.. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

OPERATION ACTIVITIES: (months) (months) (months) Note that State state of the close to net cash used in operating activities: (months) (months) Depreciation and amortization 70 2.80 Provision for soles returns 6 3.00 Stock-based compensation 12,610 1,70 Clain from increase of contingent earn-out liability fair value 6 4.02 Loss entinguishment of High Trail December 2002 and rebranay 2021 Ferm Loan 6 1.83 Loss continuity fair trail December 2002 and rebranay 2021 Term Loan 6 1.83 Loss continuity fair trail December 2002 and rebranay 2021 Term Loan 6 1.83 Loss continuity fair trailing tra			Six Months E	nded Jun	ne 30,
Nel loss \$ 1,795 \$ 1,1859 Adjustments to reconcile nel loss to net cash used in operating activities: 79 2,885 Depreciation and amoritzation 25 607 Annotzation of deferred financing costs and delix discounts 25 607 Annotzation of deferred financing costs and delix discounts 25,801 70,704 Confunction incress of contingent earn-out liability fair value 22,601 70,704 Loss in connection with the change in warrant fair value 30,801 23,438 Loss continguishment of Ford Trail December 2020 and February 2021 Term Loan 30,201 1,834 Loss continuits dissance of warrant 30,201 1,834 Loss continuits dissance of warrant 70 4,537 Contract of code/field accounts and other 7,522 4,537 Contract of code/field accounts and other liabilities 6,823 1,012 Accounts receivable 8,866 1,027 Inventory 8,866 1,027 Perpaid and other corrent asses 1,02 4,549 Cash used in operating activities 1,02 4,549 Processit from ac			2020		2021
Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 79 2,83 Provision for sales returns 25 607 Amortization of deferred financing costs and debt discounts 610 6,378 Stock-based compessation 1,700 Costs from increase of contingent eran cont liability fair value Costs from increase of contingent eran cont liability fair value Los from increase of contingent eran cont liability fair value Los from increase of contingent eran cont liability fair value Los from increase of contingent eran cont liability fair value Los from increase of contingent eran contingent Los from increase of contingent eran contingent Los from included deferiously eran late Los from including erangent Los from incl	OPERATING ACTIVITIES:				
Depectation and amotization 75 2,885 76,075 76,	Net loss	\$	(17,967)	\$	(118,859)
Provision for sales returns	Adjustments to reconcile net loss to net cash used in operating activities:				
Amortization of deferred financing costs and debt discounts 1,376 1,376 Stock-based compensation 1,2610 1,776 Cain from increase of contingent earn-out liability fair value — 4,348 Loss in connection with the change in warrant fair value — 2,243 Loss continguishment of High Trail December 2002 and February 2021 Term Loan — 2,243 Loss continguishment of Credit Facility — 2,014 Allowance for doubtful accounts and other — 2,021 Changes in seases and liabilities — 1,032 Inventory 8,866 (1,772) Pendad and one current assets 8,866 (1,772) Repaid and one current assets 8,866 (1,772) Repaid and one current assets 8,866 (1,772) Pendad assets (1,922) (5,53) Inventory of proteing activities (2,922) (5,53) Inventory of protein activities (2,922) (5,53) Inventory of protein protein activities (2,922) (2,528) Inventory of protor protein protein activities (2,922) (2,528)					
Stock-based compensation			25		607
Casin from increase of contingent carn-out liability fair value	Amortization of deferred financing costs and debt discounts		610		
A 5,589			12,610		
Loss extinguishment of High Trail December 2004 and February 2021 Term Loss — 1,894 Loss cutinguishment of Credit Facility — 1,532 Loss on tinital issuance of warrant — 2,014 Allowance for doubtful accounts and other 7 (%,075) Changes in assets and liabilities: — (7,672) (10,765) Inventory 8,866 (3,172) Prepaid and other current assets (1,269) (6,555) Accounts receivable (8,23) (3,055) Cash used in operating activities (8,23) (3,055) Cash used in operating activities (8,23) (3,055) VESTING ACTIVITIES: — (1,060) (4,049) Purchase of Floto Paper Direct, net of cash acquired — (1,053) (3,049) Purchase of Photo Paper Direct, net of cash acquired — (1,053) (3,049) Purchase of Photo Paper Direct, net of cash acquired — (1,053) (3,049) Purchase of Photo Paper Direct, net of cash acquired — (1,053) (3,049) (3,052) (3,053) (3,053) (3,053			_		
Loss from embedded derivative related to tem loan			_		
Loss extinguishment of Credit Facility			_		
Cass on initial issuance of warrant 27 4.57 Allowance for doubfulf allocacounts and other 27 4.57 Changes in assets and liabilities: Accounts receivable 6,622 6,625 Inventory 6,625 6,625 6,625 Accounts payable, accrued and other liabilities 6,625 6,625 Accounts payable, accrued and other liabilities 6,625 Cash used in operating activities 7,622 7,625 Cash used in operating activities 7,622 7,625 Durchase of fixed assets 7,622 7,625 Durchase of fixed assets 7,622 7,625 Durchase of Photo Paper Direct, net of cash acquired 7,625 7,625 Durchase of Photo Paper Direct, net of cash acquired 7,625 7,625 Durchase of Squatty Dotty assets 7,625 7,625 Durchase of Squatty Dotty assets 7,625 7,625 Durchase of Inventorial Cash acquired 7,625 7,625 Durchase of Inventorial Cash acqui			_		
Allovance for doubtful accounts and other Changes in series and liabilities: Changes in series and liabilities: (7.62) (10.736) (10.7					
Accouns recivable (7.622) (10.766) Accouns recivable (nivertory) 8.866 (31.772) Prepaid of other current assets (1.269) (6.545) Accounts payable, accrued and other liabilities (2.82) 30.151 Cash used in operating activities 8.623 30.2385 INVESTING ACTIVITIES: 8.623 (1.5280) Purchase of Healing Solutions assets 9 (1.5280) Purchase of Photo Paper Divertor, et of cash acquired 9 (1.5280) Purchase of Squatty porty assets 9 (1.904) (4.494) Cash used in investing activities 19 (4.4947) FINANCING ACTIVITIES: - 9.051 Proceeds from warrant exercis - 9.051 Proceeds from warrant exercis - 4.052 Proceeds from warrant exercis - 5.057 Proceeds from exercise of stock options - 6.735 Repayments on note payable related to Aussie Health acquisition (207) - Repayments on note payable related to Aussie Health acquisition (80.23) (82.242) <tr< td=""><td></td><td></td><td>_</td><td></td><td>,</td></tr<>			_		,
Accounts receivable (7,522) (10,736) Inventory 8,866 (31,722) Prepaid and other current assets (1,269) (6,543) Accounts payable, accrued and other liabilities (4,282) 30,151 Cash used in operating activities (8,923) 30,2836 INVESTING ACTIVITIES: (19) (44) Purchase of fladel asets (19) (45,280) Purchase of Photo Paper Direct, net of cash acquired ————————————————————————————————————	Allowance for doubtful accounts and other		27		4,597
Inventory	Changes in assets and liabilities:				
Prepaid and other current assets	Accounts receivable		(7,622)		(10,736)
Accounts payable, accrued and other liabilities (4,28) 30,151 Cash used in operating activities (8,23) (2,328) INNESTING ACTIVITIES: (19) (44) Purchase of Irkeal assets — (10,528) (15,280) Purchase of Phone Paper Direct, net of cash acquired — (10,600) (10,600) Purchase of Squaty Potry assets — (10,600) (10,600) Cash used in investing activities — (10,600) (10,600) Cash used in investing activities — (10,600) (10,600) Cash used in investing activities — (10,600) (10,600) Proceeds from variant exercise — (10,600) (10,600) Proceeds from accruitation of warrant — (20,700) (10,700) Proceeds from exercise of stock options — (20,700) (20,700) Proceeds from exercise of stock options — (20,700) (20,700) Proceeds from exercise of stock options — (20,700) (20,700) Proceeds from exercise of stock options — (20,700) (20,700) Repayment of note payable related to Aussie feath acquisition — (20,700) (20,700)	Inventory		8,866		(31,772)
Cash used in operating activities (8,935) (32,836) INVESTING ACTIVITIES: (19) (44) Purchase of Hacling Solutions assets (15,280) (15,280) Purchase of Photo Paper Direct, net of cash acquired — (10,080) Purchase of Squatty Potty assets — (19,040) Quitable of inviewing activities — (19,000) Cast used in inviewing activities — 8,051 Proceeds from varrant exercise — 6,075 Proceeds from equity offering, net of issuance costs — 6,075 Proceeds from exercise of stock options — 6,075 Proceeds from exercise of stock options — 7,050 Repayment on not peayable to Smash — 7,050 Taxes paid related to act settlement upon vesting of restricted common stock (11) 1 Borrowings from MidCap credit facility 56,181 14,000 Repayments from MidCap credit facility — (50,500 Repayments from MidCap credit facility — (50,500 Repayments from High Trail April 2021 Note — 1,000 <td>Prepaid and other current assets</td> <td></td> <td>(1,269)</td> <td></td> <td>(6,545)</td>	Prepaid and other current assets		(1,269)		(6,545)
Purchase of fixed assets 19	Accounts payable, accrued and other liabilities		(4,282)		30,151
Purchase of Ikaelians Solutions assets (15,280) Purchase of Healing Solutions assets — (15,280) Purchase of Photo Paper Direct, net of cash acquired — (10,083) Purchase of Squatty Potty assets — (19,040) Cash used in investing activities — (19,040) FINATCING ACTIVITIES: — — 9,051 Proceeds from cancellation of avarrant — — 16,957 Proceeds from exercise of stock options — — 8,749 Repayment of note payable related to Aussie Health acquisition (207) — 7,503 Taxes paid related to net settlement upon vesting of restricted common stock (112) — 6,763 Borrowings from MidCap credit facility (60,023) (28,274) 1,615 — 1,615 — 1,610 — 1,615 — 1,625 — 7,630 3,673 — 1,626 — 7,630 3,673 — 6,623 2,6274 — 6,6023 2,6274 — 6,6023 2,6274 — 1,615	Cash used in operating activities		(8,923)		(32,836)
Purchase of Photo Paper Direct, net of cash acquired	INVESTING ACTIVITIES:				
Purchase of Photo Paper Direct, net of cash acquired — (10,83) Purchase of Squatty Potty assets — (19,040) Cash used in investing activities (19,040) FINACING ACTIVITIES: — 9,051 Proceeds from cancellation of warrant — 16,957 Proceeds from equity offering, net of issuance costs — 8,749 Proceeds from exercise of stock options — 8,749 Repayment of note payable related to Aussie Health acquisition — (7,503) Texe paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility (50,023) (28,274) Deferred financing costs from MidCap credit facility — (59,500) Borrowings from High Trail Portary 2021 Note — (59,500) Borrowings from High Trail April 2021 Note — (1,002) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (1,002) Debt issuance costs from High Trail April 2021 Note — (1,002) Debt issuanc	Purchase of fixed assets		(19)		(44)
Purchase of Squatty Potry assets	Purchase of Healing Solutions assets		<u>`</u> _`		(15,280)
Cash used in investing activities (49,97) FINANCING ACTIVITIES: - 9,051 Proceeds from warrant exercise - 9,051 Proceeds from calcilation of warrant - 36,735 Proceeds from equity offering, not of issuance costs - 8,749 Proceeds from exercise of stock options - 8,749 Repayments on note payable related to Aussie Health acquisition (207) - Repayments on note payable to Smash (112) - Taxes paid related to net settlement upon vesting of restricted common stock (112) - Borrowings from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility - (151) Repayments from High Trail Perbuary 2021 Note and February 2021 Note - (59,500) Borrowings from High Trail February 2021 Note - (1,000) Debt issuance costs from High Trail April 2021 Note - (2,200) Deferred offering costs (1,315) - Insurance foligation payments (1,462) - Debt issuance costs from High Trail April 2021 Note	Purchase of Photo Paper Direct, net of cash acquired		_		(10,583)
FINANCING ACTIVITIES: — 9,051 Proceeds from warrant exercise — 9,051 Proceeds from cancellation of warrant — 16,957 Proceeds from equity offering, net of issuance costs — 8,749 Proceeds from exprise of stock options — 8,749 Repayment of note payable related to Aussie Health acquisition (207) — Repayment of note payable related to be settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility (60,023) (28,274) Bereaments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail April 2020 Note and February 2021 Note — (152) Borrowings from High Trail April 2021 Note — (1,402) Borrowings from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs 1,577 2,424			_		(19,040)
FINANCING ACTIVITIES: — 9,051 Proceeds from warrant exercise — 9,051 Proceeds from cancellation of warrant — 16,957 Proceeds from equity offering, net of issuance costs — 8,749 Proceeds from exprise of stock options — 8,749 Repayment of note payable related to Aussie Health acquisition (207) — Repayment of note payable related to be settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility (60,023) (28,274) Bereaments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail April 2020 Note and February 2021 Note — (152) Borrowings from High Trail April 2021 Note — (1,402) Borrowings from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs 1,577 2,424	Cash used in investing activities		(19)		(44,947)
Proceeds from cancellation of warrant — 16,957 Proceeds from equity offering, net of issuance costs — 36,735 Proceeds from equity offering, net of issuance costs — 8,749 Repayment of note payable related to Aussie Health acquisition (207) — Repayments on note payable to Smash — (503) Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility (60,023) (28,741) Repayments from MidCap credit facility — (151) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (155,00) Borrowings from High Trail April 2021 Note — (1,462) Borrowings from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (1,462) Deferred offering costs (1,315)			` ′		, , ,
Proceeds from equity offering, net of issuance costs — 36,735 Proceeds from exercise of stock options — 8,749 Repayments on note payable related to Aussie Health acquisition (207) — Repayments on note payable to Smash — (7,503) Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (59,500) Borrowings from High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail February 2021 Note — (1,402) Borrowings from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (1,462) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital tease obligation payments (4) — Gash p	Proceeds from warrant exercise		_		9,051
Proceeds from exercise of stock options — 8,749 Repayment of note payable to Bandsh (207) — Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (15,9500) Borrowings from High Trail Epecary 2021 Note — 14,025 Borrowings from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance obligation payments (4) — Capital lease obligation payments (4) — Legent of financing activities (4) — EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD 30,789 </td <td>Proceeds from cancellation of warrant</td> <td></td> <td>_</td> <td></td> <td>16,957</td>	Proceeds from cancellation of warrant		_		16,957
Proceeds from exercise of stock options — 8,749 Repayment of note payable to Bandsh (207) — Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (15,9500) Borrowings from High Trail Epecary 2021 Note — 14,025 Borrowings from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance obligation payments (4) — Capital lease obligation payments (4) — Legent of financing activities (4) — EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD 30,789 </td <td>Proceeds from equity offering, net of issuance costs</td> <td></td> <td>_</td> <td></td> <td>36,735</td>	Proceeds from equity offering, net of issuance costs		_		36,735
Repayment of note payable related to Aussie Health acquisition (207) — Repayments on note payable to Smash — (7,503) Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility — (151) Deferred financing costs from MidCap credit facility — (59,500) Borrowings from High Trail Pectuary 2021 Note — 14,025 Borrowings from High Trail Pebruary 2021 Note — (1,000 Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (13) — (2,200) Deferred offering costs (14) — (2,200) Insurance obligation payments (1,25) (1,2			_		
Repayments on note payable to Smash — (7,503) Taxe spaid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (59,500) Repayments for High Trail Gebruary 2020 Note and February 2021 Note — (1,025) Borrowings from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail February 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4,218) 11,924 EFFECT OF EXCHANGE RATE ON CASH 1 (1,557) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRI			(207)		
Taxes paid related to net settlement upon vesting of restricted common stock (112) — Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail February 2021 Note — 11,025 Borrowings from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance offering costs (1,39) — Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4,18) 11,572 Cash provided by financing activities (4,218) 11,575 NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (31,39) 30,097 C			`		(7,503)
Borrowings from MidCap credit facility 56,181 14,630 Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail April 2021 Note — 110,000 Debt issuance costs from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (33,759) 30,097 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 64,063 RECONCILIATION OF CASH AND RESTRIC			(112)		_
Repayments from MidCap credit facility (60,023) (28,274) Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail February 2021 Note — 110,000 Debt issuance costs from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail February 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Capital lease obligation payments (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (3),789 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,630 \$ 64,063 RESTRICTED CASH—Prepaid					14.630
Deferred financing costs from MidCap credit facility — (151) Repayments for High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail February 2021 Note — (14,025) Borrowings from High Trail April 2021 Note — (1,462) Debt issuance costs from High Trail February 2021 Note — (2,200) Deferred offering cost (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds (1,577) 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AND RESTRICTED CASH \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					,
Repayments for High Trail December 2020 Note and February 2021 Note — (59,500) Borrowings from High Trail February 2021 Note — 14,025 Borrowings from High Trail April 2021 Note — (1,062) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (31,559) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		
Borrowings from High Trail February 2021 Note — 14,025 Borrowings from High Trail April 2021 Note — 110,000 Debt issuance costs from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,622 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		, ,
Borrowings from High Trail April 2021 Note — 110,000 Debt issuance costs from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		
Debt issuance costs from High Trail February 2021 Note — (1,462) Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD (13,159) 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		
Debt issuance costs from High Trail April 2021 Note — (2,200) Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		
Deferred offering costs (139) — Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			_		, ,
Insurance obligation payments (1,491) (1,557) Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129			(130)		(2,200)
Insurance financing proceeds 1,577 2,424 Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					(1 557)
Capital lease obligation payments (4) — Cash provided by financing activities (4,218) 111,924 EFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					
Cash provided by financing activities (4,218) 111,924 EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					2,424
EFFECT OF EXCHANGE RATE ON CASH 1 (175) NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129	1 6 1 7				111 024
NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD (13,159) 33,966 CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129	i j				
CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD 30,789 30,097 CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					
CASH AND RESTRICTED CASH AT END OF PERIOD \$ 17,630 \$ 64,063 RECONCILIATION OF CASH AND RESTRICTED CASH \$ 17,189 \$ 61,934 CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					
RECONCILIATION OF CASH AND RESTRICTED CASH CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129		Φ.		•	
CASH \$ 17,189 \$ 61,934 RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129		\$	17,630	\$	64,063
RESTRICTED CASH—Prepaid and other assets 312 2,000 RESTRICTED CASH—Other non-current assets 129 129					
RESTRICTED CASH—Other non-current assets 129 129		\$		\$	- /
					2,000
TOTAL CASH AND RESTRICTED CASH \$ 17,630 \$ 64,063	RESTRICTED CASH—Other non-current assets		129		129
	TOTAL CASH AND RESTRICTED CASH	\$	17,630	\$	64,063

ATERIAN, INC. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION		
Cash paid for interest	\$ 1,618	\$ 1,727
Cash paid for taxes	\$ 46	\$ 41
NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Equity fundraising costs not paid	\$ _	\$ 125
Original issue discount	\$ _	\$ 2,475
Fair value of contingent consideration	\$ _	\$ 20,971
Discount of debt relating to warrants issuance	\$ _	\$ 46,756
Issuance of restricted stock awards	\$ _	\$ 3,427
Issuance of common stock in connection with Healing Solutions and Photo Paper Direct acquisitions	\$ _	\$ 50,529
Common stock issued to High Trail	\$ _	\$ 4,056
Reclassification of warrants to equity	\$ _	\$ 80,022

Non-GAAP Financial Measures

We believe that our financial statements and the other financial data included in this Quarterly Report on Form 10-Q have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles in the United States ("GAAP"). However, for the reasons discussed below, we have presented certain non-GAAP measures herein.

We have presented the following non-GAAP measures to assist investors in understanding our core net operating results on an on-going basis: (i) Contribution margin; (ii) Contribution margin as a percentage of net revenue; (iii) Adjusted EBITDA; and (iv) Adjusted EBITDA as a percentage of net revenue. These non-GAAP financial measures may also assist investors in making comparisons of our core operating results with those of other companies.

As used herein, Contribution margin represents operating loss plus general and administrative expenses, research and development expenses, fixed sales, distribution expenses and amortization of inventory step-up from acquisitions (included in cost of goods sold). As used herein, Contribution margin represents operating loss plus general and administrative expenses, research and development expenses, fixed sales, distribution expenses and amortization of inventory step-up from acquisitions (included in cost of goods sold). As used herein, Contribution margin as a percentage of net revenue represents Contribution margin divided by net revenue. As used herein, EBITDA represents net loss plus depreciation and amortization, interest expense, net and income tax expense. As used herein, Adjusted EBITDA represents EBITDA plus stock-based compensation expense, changes in fair-market value of earnouts, amortization of inventory step-up from acquisitions (included in cost of goods sold), changes in fair-market value of warrant liability, loss on initial issuance of warrant, professional fees and transition fees related to acquisitions, reserve on dispute with a PPE supplier, loss from extinguishment of debt and other expenses, net. As used herein, Adjusted EBITDA as a percentage of net revenue represents Adjusted EBITDA divided by net revenue. Contribution margin, EBITDA and Adjusted EBITDA do not represent and should not be considered as alternatives to loss from operations or net loss, as determined under GAAP.

We present Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue because we believe each of these measures provides an additional metric to evaluate our operations and, when considered with both our GAAP results and the reconciliation to net loss, provides useful supplemental information for investors. We use Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue, together with financial measures prepared in accordance with GAAP, such as sales and gross margins, to assess our historical and prospective operating performance, to provide meaningful comparisons of operating performance across periods, to enhance our understanding of our operating performance and to compare our performance to that of our peers and competitors.

We believe EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue are useful to investors in assessing the operating performance of our business without the effect of non-cash items, while Contribution margin and Contribution margin as a percentage of net revenue are useful to investors in assessing the operating performance of our products as they represent our operating results without the effects of fixed costs and non-cash items. Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue should not be considered in isolation or as alternatives to net loss, loss from operations or any other measure of financial performance calculated and prescribed in accordance with GAAP. Neither EBITDA, Adjusted EBITDA nor Adjusted EBITDA as a percentage of net revenue should be considered a measure of discretionary cash available to us to invest in the growth of our business. Our Contribution margin, Contribution margin as a percentage of net revenue, EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue may not be comparable to similar titled measures in other organizations because other organizations may not calculate Contribution margin, EBITDA, Adjusted EBITDA or Adjusted EBITDA as a percentage of net revenue in the same manner as we do. Our presentation of Contribution margin and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by the expenses that are excluded from such terms or by unusual or non-recurring items.

We recognize that EBITDA, Adjusted EBITDA and Adjusted EBITDA as a percentage of net revenue, have limitations as analytical financial measures. For example, neither EBITDA nor Adjusted EBITDA reflects:

Exhibit 99.1

- our capital expenditures or future requirements for capital expenditures or mergers and acquisitions;
- the interest expense or the cash requirements necessary to service interest expense or principal payments, associated with indebtedness;
- depreciation and amortization, which are non-cash charges, although the assets being depreciated and amortized will likely have to be replaced in the future, or any cash requirements for the replacement of assets;
- changes in cash requirements for our working capital needs; or
- changes in fair value of contingent earn-out liabilities, warrant liabilities, and amortization of inventory step-up from acquisitions (included in cost of goods sold) and transition costs from acquisitions.

Additionally, Adjusted EBITDA excludes non-cash expense for stock-based compensation, which is and is expected to remain a key element of our overall long-term incentive compensation package.

We also recognize that Contribution margin and Contribution margin as a percentage of net revenue have limitations as analytical financial measures. For example, Contribution margin does not reflect:

- general and administrative expense necessary to operate our business;
- · research and development expenses necessary for the development, operation and support of our software platform;
- · the fixed costs portion of our sales and distribution expenses including stock-based compensation expense; or
- changes in fair value of contingent earn-out liabilities, warrant liabilities, and amortization of inventory step-up from acquisitions (included in cost of goods sold).

Contribution Margin

Contribution margin represents operating loss plus general and administrative expenses, research and development expenses, fixed sales and distribution expenses, changes in fair-market value of earn-outs and amortization of inventory step-up from acquisitions (included in cost of goods sold). Contribution margin as a percentage of net revenue represents Contribution margin divided by net revenue. The following table provides a reconciliation of Contribution margin to operating loss, which is the most directly comparable financial measure presented in accordance with GAAP.

		Three Months I	Ended	June 30,		une 30,		
		2020		2021		2020		2021
		(in thousands, exc	ept pe	rcentages)		(in thousands, exc	ept pe	rcentages)
Operating loss	\$	(1,821)	\$	4,468	\$	(15,717)	\$	(23,286)
Add:								
General and administrative expenses		8,352		9,990		16,355		20,965
Research and development expenses		2,451		2,324		4,732		4,452
Sales and distribution fixed expenses, including								
stock-based compensation expense		1,054		9,995		3,911		13,327
Change in fair value of contingent earn-out liabilities				(23,349)		_		(7,704)
Amortization of inventory step-up from acquisitions (included in cost								
of goods sold)		<u> </u>		2,233		<u> </u>		4,041
Contribution margin	\$	10,036	\$	5,661	\$	9,281	\$	11,795
Contribution margin as a percentage of net								
revenue		16.8%		8.3%		10.9%		10.1%

Adjusted EBITDA

EBITDA represents net loss plus depreciation and amortization, interest expense, net and income tax expense. Adjusted EBITDA represents EBITDA plus stock-based compensation expense, changes in fair-market value of earn-outs, amortization of inventory step-up from acquisitions (included in cost of goods sold), change in fair-market value of warrant liability, loss on initial issuance of warrant, professional fees and transition fees related to acquisitions, reserve on dispute with a PPE supplier, loss from extinguishment of debt and other expenses, net. As used herein, Adjusted EBITDA as a percentage of net revenue represents Adjusted EBITDA divided by net revenue. The following table provides a reconciliation of EBITDA and Adjusted EBITDA to net loss, which is the most directly comparable financial measure presented in accordance with GAAP:

		Three Months I	nded .	June 30,	Six Months Ended June 30,						
		2020		2021		2020		2021			
	_	(in thousands, exc			_	(in thousands, exc					
Net loss	\$	(2,937)	\$	(36,306)	\$	(17,967)	\$	(118,859)			
Add:											
Provision for income taxes		45		41		45		41			
Interest expense, net		1,077		4,675		2,186		9,092			
Depreciation and amortization		38		1,681		79		2,885			
EBITDA		(1,777)	<u> </u>	(29,909)		(15,657)		(106,841)			
Other expense (income), net		(6)		(5)		19		(38)			
Change in fair value of contingent earn-out liabilities		_		(23,349)		_		(7,704)			
Amortization of inventory step-up from acquisitions (included in											
cost of goods sold)		_		2,233		_		4,041			
Change in fair market value of warrant liability		_		4,387		_		34,589			
Change in fair value of derivative liability		_		1,894		_		1,894			
Loss on extinguishment of debt				29,772		_		29,772			
Loss on initial issuance of warrant		_		_		_		20,147			
Professional fees related to acquisitions				948		_		1,397			
Transition costs from acquisitions		_		632		_		1,184			
Professional fees related to Photo Paper Direct acquisitions		_		696		_		696			
Reserve on dispute with PPE supplier		_		4,100		_		4,100			
Stock-based compensation expense		5,171		4,862		12,610		11,760			
Adjusted EBITDA	\$	3,388	\$	(3,739)	\$	(3,028)	\$	(5,003)			
Adjusted EBITDA as a percentage of net											
revenue		5.7%		(5.5)%		(3.5)%		(4.3)%			

We believe each of our products goes through three core phases as follows:

- i. Launch phase: During this phase, we leverage our technology to target opportunities identified using AIMEE. During this period of time, and due to the combination of discounts and investment in marketing, our net margin for a product could be as low as negative 35%. In general, a product may stay in the launch phase on average for 3 months.
- ii. Sustain phase: Our goal is for every product we launch to enter the sustain phase and become profitable, with a target average of positive 10% net margin (i.e. contribution margin). Over time, our products benefit from economies of scale stemming from purchasing power both with manufacturers and with fulfillment providers.
- iii. Liquidate phase: If a product does not enter the sustain phase or if the customer satisfaction of the product (i.e., ratings) are not satisfactory, then it will go to the liquidate phase and we will sell the remaining inventory.

The following table breaks out our quarterly results of operations by our product phases including our PaaS business line:

Three months ended June 30, 2020 (in thousands) (unaudited)

										ixed		ock-based npensation		
	9	Sustain	L	aunch	J	PaaS	Liq	uidate/Other	C	osts	(expense		Total
NET REVENUE	\$	44,047	\$	5,655	\$	347	\$	9,751	\$	_	\$	_	\$	59,800
COST OF GOODS SOLD		23,184		3,032		_		5,984		_		_		32,200
GROSS PROFIT		20,863		2,623		347		3,767					_	27,600
OPERATING EXPENSES:														
Sales and distribution		12,142		2,326		129		2,967		1,633		(579)		18,618
Research and development		_		_		_				1,272		1,179		2,451
General and administrative		_		_		_		_		3,781		4,571		8,352

Three months ended June 30, 2021 (in thousands) (unaudited)

										Stock-based	
							I	ixed	(compensation	
	Sustain	L	aunch]	PaaS	Liquidate/Other	(Costs		expense	Total
NET REVENUE	\$ 61,764	\$	4,358	\$	92	\$ 1,974	\$	_	\$	_	\$ 68,188
COST OF GOODS SOLD (1)	28,555		3,464			3,426				_	35,445
GROSS PROFIT	33,209		894		92	(1,452)				_	32,743
OPERATING EXPENSES:						 _					
Sales and distribution	25,412		2,131		_	1,765		8,433		1,569	39,310
Research and development	_		_		_	_		1,103		1,221	2,324
General and administrative	_		_		_	_		7,918		2,072	9,990

(1) Sustain cost of goods sold includes \$2.2 million of amortization of inventory step-up from acquisitions

Six months ended June 30, 2020 (in thousands) (unaudited)

	Sustain	Launch	PaaS	Liquidate/Other	Fixed Costs	compensation expense	Total
NET REVENUE	60,951	\$ 11,809	\$ 708	\$ 11,960	<u> </u>	<u> </u>	\$ 85,428
COST OF GOODS SOLD	32,877	6,637		8,016			47,530
GROSS PROFIT	28,074	5,172	708	3,944			37,898
OPERATING EXPENSES:		·					
Sales and distribution	18,280	5,479	217	4,641	2,898	1,013	32,528
Research and development		_		_	2,280	2,452	4,732
General and administrative	_	_	_	_	7,209	9,146	16,355

Six months ended June 30, 2021 (in thousands) (unaudited)

										Stock-based	
	Sustain	L	aunch	P	aaS	Liquidate/Other		Fixed Costs	C	ompensation expense	Total
NET REVENUE	\$ 103,710	\$	6,957	\$	273	\$ 	_	_	\$	_	\$ 116,324
COST OF GOODS SOLD (1)	45,860		4,916		_	6,742		_		_	57,518
GROSS PROFIT	57,850		2,041		273	(1,358)					58,806
OPERATING EXPENSES:											
Sales and distribution	44,228		3,528		37	3,246		10,816		2,524	64,379
Research and development	_		_		_	_		2,348		2,104	4,452
General and administrative	_		_		_	_		13,833		7,132	20,965

⁽¹⁾ Sustain cost of goods sold includes \$4.0 million of amortization of inventory step-up from acquisitions